Cell & Gene by Oxford Global’s Post

The clinical drug development market is teeming with innovation, including cell and gene therapies, digital therapeutics, personalized medicine and biomarkers, and the integration of drugs and medical devices. However, despite these breakthroughs, many life sciences organizations are not able to fully capitalize on the advancements. Does your organization possess the advanced digital and data capabilities to harness the new trial designs and operating models that will increase program efficiency, speed, and access?   Read our latest POV 👇https://bit.ly/3SKtKT1 #LifeSciences #ClinicalDevelopment #Innovation #nextgenclinicaldevelopment 

Intellia Therapeutics has unveiled strong clinical data showing the feasibility of redosing their CRISPR-based therapy, NTLA-2001, using a LNP system. Administering a second, higher dose resulted in a significant 90% median reduction in serum TTR levels among patients with transthyretin amyloidosis. While redosing isn't currently planned for this program, the findings suggest potential benefits for future therapies. YolTech's proprietary in vivo gene editing therapy, YOLT-201, also utilizes LNP delivery system to achieve efficient TTR gene knockout in patients. In precious investigator-initiated trial (IIT), all patient enrollments have been completed, showcasing excellent clinical data with significant preliminary efficacy and safety. Stay tuned for more good news. #GeneTherapy #CRISPR #LNP #ClinicalData #Biotechnology #HealthcareInnovation #YolTech #IntelliaTherapeutics

The clinical drug development market is teeming with innovation, including cell and gene therapies, digital therapeutics, personalized medicine and biomarkers, and the integration of drugs and medical devices. However, despite these breakthroughs, many life sciences organizations are not able to fully capitalize on the advancements. Does your organization possess the advanced digital and data capabilities to harness the new trial designs and operating models that will increase program efficiency, speed, and access? Read our Point of view 👇 https://bit.ly/48ArUK7 #lifesciences #clinicaldevelopment #Innovation #nextgenclinicaldevelopment 

What is top of mind across cell therapy?... While ISCT, International Society for Cell & Gene Therapy annual meeting is in the rearview, the highlights, key trends, and hurdles remain! We asked stakeholders from companies like Ori Biotech, xcellbio, and uBriGene Biosciences Inc., and investors from AVANT BIO what their key takeaways are. Check it out here: 👉 https://lnkd.in/dEUWbKAi The long and short, you ask? 1️⃣ Manufacturing Innovations and Challenges: The field is rapidly advancing with new automated platforms to address current suboptimal workflows. 2️⃣ Technological Advancements and Excitement: The conference saw multiple launches of new systems, like Ori's IRO®, Cytiva's enhanced Sefia system, and Xcellbio's AVATAR. 3️⃣ Focus on Potency and Data-Driven Processes: There was a strong emphasis on developing better potency assessments and leveraging data-driven processes. Did you attend the conference? What was your key takeaway? Let me know! #celltherapy #pharma #healthcare

Innovation brings opportunity. But just as often, it introduces complexity. For life sciences organizations, that is certainly the case. Cell and gene therapies, digital therapeutics, personalized medicine, biomarkers, and the integration of drugs and medical devices have sparked incredible advancements for the industry, but they have also created new challenges when it comes to clinical trials.  Our new POV, Next-Generation Clinical Development: Driving success and time-to-market in clinical drug development, explores how life sciences organizations can leverage powerful new digital and data capabilities, as well as new trial designs, to cut clinical development complexity and harness the power of breakthrough innovations. Read our Point of view https://bit.ly/3SKtKT1 #lifesciences #clinicaldevelopment #Innovation #nextgenclinicaldevelopment

🌟 Exciting introduction at Advanced Therapies Week in Miami! 🌟 🎤 Important moment as Tigen takes the stage to unveil something extraordinary: the foundation of the Decentralized Manufacturing Consortium for Cell & Gene Therapies, a revolutionary initiative that will reshape the future of advanced therapies! All founding members of the Consortium joined the stage to introduce themselves and their motivation behind their Consortium contribution – a remarkable moment. 🌈💡 💡 We are happy to be part of that Consortium, a passionate group of cell therapy manufacturing experts from around the world who joined forces in Mannheim in December. Our goal is to align on a plan to accelerate the development of decentral supply for cell therapies. 🧬 Decentralized manufacturing is the “next big thing” – a clear takeaway of this year's Phacilitate. In one or the other way, every second talk touched decentralized manufacturing models or related contents – and with that indirectly Hypertrust X-Chain platform, which executes the supply chain and manufacturing protocols of all today’s publicly known autologous therapy assets produced in a decentralized set-up. #ATW2024 #Hypertrust Tigen Adva Biotechnology Blood Centers of America Swissfinity Group Hitachi Cellex Cell Professionals Arvato

Coming up this Wednesday at 2pm EDT! Register now for BioCentriq's upcoming webinar on the role of platform processes in cell therapy: https://lnkd.in/dWdf9eXV To give you valuable insights, we're bringing a panel of experts that includes moderator Alex Klarer, VP of Business Strategy and Innovation at BioCentriq; Taby Ahsan, VP of Cell & Gene Therapy Operations at City of Hope; and Michael Kuo, Senior VP of Manufacturing at Vita Therapeutics. The hypothesis being discussed is whether the adoption of platform processes will help cell therapy developers: -Reduce development and manufacturing costs -Accelerate timelines -Scale their manufacturing faster -Minimize skill gaps -Address workforce shortages -Spend more time on what makes their product effective -Get to patients faster Don't forget to register here: https://lnkd.in/dWdf9eXV #biocentriq #cellandgenetherapy #cellandgene #celltherapymanufacturing #celltherapy #cgt #biopharma #advancedtherapies #CDMO #celltherapycdmo #biotech #regenerativemedicine #atmp #IND #clinicaltrials #lifesciences #cartcr #webinar #biotechnology #webinar

Check out how we utilize the modularity of the Pin-point™ platform, the aptamer-recruited base editing system, to introduce multiple discrete modifications simultaneously, including targeted integration, and to create complex edited cell therapies in one-step process. Our paper is now published in #MolecularTherapy https://lnkd.in/dEh3g92r

At Revive Medical Technologies Inc., we're leveraging the groundbreaking potential of Carbon Quantum Dots (CQDs) - tiny, photoluminescent nanoparticles, typically smaller than 10 nm. These tiny, luminescent nanoparticles are opening new horizons in healthcare. CQDs have the potential to revolutionize healthcare as they have: 1.High Fluorescence & Stability 2.Low Toxicity & Eco-Friendly 3.Versatile in Drug & Gene Delivery 4.Effective in Cancer Therapy 5.innovative in Bioimaging & Biosensing Their hydrophilic surface, resistance to photobleaching, and good cellular compatibility make them safer and more efficient, especially since they are free from the heavy metals often used in semiconductor dots. At Revive Medical Technologies, we're leveraging their groundbreaking potential in many unique applications, to play our part in revolutionizing healthcare. #CarbonQuantumDots #ReviveMedicalTechnologies #BiomedicalInnovation #FutureOfHealthcare #NanoTechnology #GlobalHealth #CuttingEdgeScience

Read our new feature article to learn how non-viral CRISPR editing systems are ushering in the next wave of cell therapies.✌️ https://ow.ly/X4js50QfkW8 Featuring insights from experts in the field, we explore topics including the advantages of non-viral delivery over viral methods, methods researchers are using to overcome the low efficiency of non-viral delivery, and services currently available to help labs make the switch to non-viral delivery. #newarticle #CRISPR #celltherapy #nonviral #geneservices #lab #nonviraldelivery #biotech #biologyservice